Usability of a smartwatch for atrial fibrillation detection in older adults after stroke

Eric Y Ding, Maira CastañedaAvila, Khanh-Van Tran, Jordy Mehawej, Andreas Filippaios, Tenes Paul, Edith Mensah Otabil, Kamran Noorishirazi, Dong Han, Jane S Saczynski, Bruce Barton, Kathleen M Mazor, Ki Chon, David D McManus, Eric Y Ding, Maira CastañedaAvila, Khanh-Van Tran, Jordy Mehawej, Andreas Filippaios, Tenes Paul, Edith Mensah Otabil, Kamran Noorishirazi, Dong Han, Jane S Saczynski, Bruce Barton, Kathleen M Mazor, Ki Chon, David D McManus

Abstract

Background: Smartwatches can be used for atrial fibrillation (AF) detection, but little is known about how older adults at risk for AF perceive their usability.

Methods: We employed a mixed-methods study design using data from the ongoing Pulsewatch study, a randomized clinical trial (NCT03761394) examining the accuracy of a smartwatch-smartphone app dyad (Samsung/Android) compared to usual care with a patch monitor (Cardea SOLO™ ECG System) for detection of AF among older stroke survivors. To be eligible to participate in Pulsewatch, participants needed to be at least 50 years of age, have had an ischemic stroke, and have no major contraindications to anticoagulation therapy should AF be detected. After 14 days of use, usability was measured by the System Usability Scale (SUS) and investigator-generated questions. Qualitative interviews were conducted, transcribed, and coded via thematic analysis.

Results: Ninety participants in the Pulsewatch trial were randomized to use a smartwatch-smartphone app dyad for 14 days (average age: 65 years, 41% female, 87% White), and 46% found it to be highly usable (SUS ≥68). In quantitative surveys, participants who used an assistive device (eg, wheelchair) and those with history of anxiety or depression were more likely to report anxiety associated with watch use. In qualitative interviews, study participants reported wanting a streamlined system that was more focused on rhythm monitoring and a smartwatch with a longer battery life. In-person training and support greatly improved their experience, and participants overwhelmingly preferred use of a smartwatch over traditional cardiac monitoring owing to its comfort, appearance, and convenience.

Conclusion: Older adults at high risk for AF who were randomized to use a smartwatch-app dyad for AF monitoring over 14 days found it to be usable for AF detection and preferred their use to the use of a patch monitor. However, participants reported that a simpler device interface and longer smartwatch battery life would increase the system's usability.

Keywords: Acceptability; Atrial fibrillation; Smartwatch; Stroke; Usability.

© 2022 Heart Rhythm Society.

Figures

Figure 1
Figure 1
Pulsewatch study structure. Data from participants in the Phase I intervention group of the Pulsewatch trial.

References

    1. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:e1–e76.
    1. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–847.
    1. Turakhia M.P., Shafrin J., Bognar K., et al. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13
    1. Alkhouli M., Alqahtani F., Aljohani S., Alvi M., Holmes D.R. Burden of atrial fibrillation-associated ischemic stroke in the United States. JACC Clin Electrophysiol. 2018;4:618–625.
    1. Jaakkola J., Mustonen P., Kiviniemi T., et al. Stroke as the first manifestation of atrial fibrillation. PLoS One. 2016;11
    1. Lin H.J., Wolf P.A., Kelly-Hayes M., et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke. 1996;27:1760–1764.
    1. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
    1. Ruff C.T., Giugliano R.P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
    1. Penado S., Cano M., Acha O., Hernández J.L., Riancho J.A. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206–210.
    1. Galli A., Ambrosini F., Lombardi F. Holter monitoring and loop recorders: from research to clinical practice. Arrhythm Electrophysiol Rev. 2016;5:136–143.
    1. Subbiah R., Gula L.J., Klein G.J., Skanes A.C., Yee R., Krahn A.D. Syncope: review of monitoring modalities. Curr Cardiol Rev. 2008;4:41–48.
    1. Zuckerman B. De novo clearance for “Study Watch” (K182456). U.S. Food & Drug Administration. Published online December 20, 2018.
    1. Krueger A.C. De novo clearance for “Irregular Rhythm Notification Feature” (DEN 180042). U.S. Food & Drug Administration. Published online September 11, 2018.
    1. Smith A. Older Adults and Technology Use. Pew Research Center: Internet, Science & Tech. Published April 3, 2014.
    1. Post-Stroke Rehabilitation Fact Sheet | National Institute of Neurological Disorders and Stroke.
    1. Schorr E.N., Gepner A.D., Dolansky M.A., et al. Harnessing mobile health technology for secondary cardiovascular disease prevention in older adults: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2021;14
    1. Zotz N., Saft S., Rosenlöhner J., Böhm P., Isemann D. In: Computers Helping People with Special Needs. Lecture Notes in Computer Science. Miesenberger K., Kouroupetroglou G., editors. Springer International Publishing; 2018. Identification of age-specific usability problems of smartwatches; pp. 399–406.
    1. Khakurel J., Knutas A., Melkas H., Penzenstadler B., Fu B., Porras J. In: Universal Access in Human-Computer Interaction. Methods, Technologies, and Users. Lecture Notes in Computer Science. Antona M., Stephanidis C., editors. Springer International Publishing; 2018. Categorization framework for usability issues of smartwatches and pedometers for the older adults; pp. 91–106.
    1. Manini T.M., Mendoza T., Battula M., et al. Perception of older adults toward smartwatch technology for assessing pain and related patient-reported outcomes: pilot study. JMIR Mhealth Uhealth. 2019;7
    1. Brooke J. Usability Evaluation in Industry. Taylor & Francis; 1996. SUS: A “Quick and Dirty” Usability Scale.
    1. Nasreddine Z.S., Phillips N.A., Bédirian V., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699.
    1. Kroenke K., Spitzer R.L., Williams J.B. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613.
    1. Spitzer R.L., Kroenke K., Williams J.B.W., Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–1097. doi: 10.1001/archinte.166.10.1092.
    1. O’Cathain A., Murphy E., Nicholl J. Three techniques for integrating data in mixed methods studies. BMJ. 2010;341:c4587.
    1. Liang J., Xian D., Liu X., et al. Usability study of mainstream wearable fitness devices: feature analysis and system usability scale evaluation. JMIR mHealth uHealth. 2018;6
    1. Keogh A., Dorn J.F., Walsh L., Calvo F., Caulfield B. Comparing the usability and acceptability of wearable sensors among older Irish adults in a real-world context: observational study. JMIR mHealth uHealth. 2020;8
    1. Farivar S., Abouzahra M., Ghasemaghaei M. Wearable device adoption among older adults: a mixed-methods study. Int J Inf Manage. 2020;55:102209.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe